Cargando…

High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation

Intimal hyperplasia is the cause of the recurrent occlusive vascular disease (restenosis). Drugs currently used to treat restenosis effectively inhibit smooth muscle cell (SMC) proliferation, but also inhibit the growth of the protective luminal endothelial cell (EC) lining, leading to thrombosis. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goel, Shakti A., Guo, Lian-Wang, Wang, Bowen, Guo, Song, Roenneburg, Drew, Ananiev, Gene E., Hoffmann, F. Michael, Kent, K. Craig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933427/ https://www.ncbi.nlm.nih.gov/pubmed/24586708 http://dx.doi.org/10.1371/journal.pone.0089349

Ejemplares similares

Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation
Publicado: (2014)

Restenosis Inhibition and Re-differentiation of TGFβ/Smad3-activated Smooth Muscle Cells by Resveratrol
por: Zhu, Yichen, et al.
Publicado: (2017)

BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries
por: Wang, Bowen, et al.
Publicado: (2015)

Analysis of Combined Transcriptomes Identifies Gene Modules that Differentially Respond to Pathogenic Stimulation of Vascular Smooth Muscle and Endothelial Cells
por: Pan, Xiaokang, et al.
Publicado: (2018)

Confocal microscopy of idarubicin localisation.
por: Manfait, M., et al.
Publicado: (1997)

Confocal microscopy of idarubicin localisation - reply
por: Duffy, P, et al.
Publicado: (1997)

ALDH1A3 Regulations of Matricellular Proteins Promote Vascular Smooth Muscle Cell Proliferation
por: Xie, Xiujie, et al.
Publicado: (2019)

HDAC6 Regulates the MRTF-A/SRF Axis and Vascular Smooth Muscle Cell Plasticity
por: Zhang, Mengxue, et al.
Publicado: (2018)

Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma
por: Chehimi, Mohamad, et al.
Publicado: (2016)

A hierarchical and collaborative BRD4/CEBPD partnership governs vascular smooth muscle cell inflammation
por: Wang, Qingwei, et al.
Publicado: (2021)

The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts
por: Dragojew, Sylwia, et al.
Publicado: (2008)

Idarubicin-bromelain combination sensitizes cancer cells to conventional chemotherapy
por: Taşkın, Abdullah, et al.
Publicado: (2019)

Idarubicin–Gold Complex: From Crystal Growth to Gold Nanoparticles
por: Barbey, Carole, et al.
Publicado: (2021)

TGF-β/Smad3 Stimulates Stem Cell/Developmental Gene Expression and Vascular Smooth Muscle Cell De-Differentiation
por: Shi, Xudong, et al.
Publicado: (2014)

Smad2 inhibition of MET transcription potentiates human vascular smooth muscle cell apoptosis
por: Xie, Xiujie, et al.
Publicado: (2021)

Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3
por: Komiyama, Tomoyoshi, et al.
Publicado: (2016)

Insights into idarubicin antimicrobial activity against methicillin-resistant Staphylococcus aureus
por: She, Pengfei, et al.
Publicado: (2020)

Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
por: Roth, Gaël Stéphane, et al.
Publicado: (2020)

Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
por: Sherif, Hemat Afifi, et al.
Publicado: (2021)

Correction to “Idarubicin–Gold Complex: From Crystal Growth to Gold Nanoparticles”
por: Barbey, Carole, et al.
Publicado: (2022)

miR548ai antagonism attenuates exosome-induced endothelial cell dysfunction
por: Xie, Xiujie, et al.
Publicado: (2021)

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
por: Zhang, Ying, et al.
Publicado: (2022)

Downregulation of TRPC4 and TRPC5 Inhibits Smooth Muscle Cell Proliferation without Affecting Endothelial Cell Proliferation
por: Zeng, Wenjun, et al.
Publicado: (2021)

Correction: miR548ai antagonism attenuates exosome-induced endothelial cell dysfunction
por: Xie, Xiujie, et al.
Publicado: (2022)

Transarterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin-Loaded Tandem Drug-Eluting Embolics
por: Guiu, Boris, et al.
Publicado: (2019)

Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea
por: Lee, Dae Hyoung, et al.
Publicado: (2010)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
por: Fan, Wenzhe, et al.
Publicado: (2022)

Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines.
por: Duffy, P. M., et al.
Publicado: (1996)

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
por: Fan, Ni, et al.
Publicado: (2017)

Carbon-based ruthenium nanomaterial-based electroanalytical sensors for the detection of anticancer drug Idarubicin
por: Kaya, S. Irem, et al.
Publicado: (2020)

Atherosclerosis Vascular Endothelial Secretion Dysfunction and Smooth Muscle Cell Proliferation
por: Li, Junxi, et al.
Publicado: (2022)

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors
por: Liu, Y, et al.
Publicado: (2013)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia
por: Yoon, Jong Hyung, et al.
Publicado: (2009)

The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Lee, Se Ryeon, et al.
Publicado: (2009)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
por: Rodríguez-Macías, Gabriela, et al.
Publicado: (2023)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

Retracted: Atherosclerosis Vascular Endothelial Secretion Dysfunction and Smooth Muscle Cell Proliferation
por: Healthcare Engineering, Journal of
Publicado: (2023)

A rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells
por: Kim, Yerin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_grfn7js0oneak3jrmtnfqvhnqn